Cytoreductive Nephrectomy and Overall Survival of Patients with
Metastatic Renal Cell Carcinoma Treated with Targeted
Therapy-Data from the National Renis Registry

J 2020

Cytoreductive Nephrectomy and Overall Survival of Patients with Metastatic Renal Cell Carcinoma Treated with Targeted Therapy-Data from the National Renis Registry

POPRACH, Alexandr, Miloš HOLÁNEK, Renata CHLOUPKOVÁ, Radek LAKOMÝ, Michal STANÍK et. al.

Basic information

Original name

Cytoreductive Nephrectomy and Overall Survival of Patients with Metastatic Renal Cell Carcinoma Treated with Targeted Therapy-Data from the National Renis Registry

Authors

POPRACH, Alexandr (203 Czech Republic, guarantor, belonging to the institution), Miloš HOLÁNEK (203 Czech Republic, belonging to the institution), Renata CHLOUPKOVÁ (203 Czech Republic, belonging to the institution), Radek LAKOMÝ (203 Czech Republic, belonging to the institution), Michal STANÍK (703 Slovakia, belonging to the institution), Ondřej FIALA (203 Czech Republic), Bohuslav MELICHAR (203 Czech Republic), Kateřina KOPECKOVA (203 Czech Republic), Milada ZEMANOVA (203 Czech Republic), Igor KISS (203 Czech Republic, belonging to the institution), Igor PENKA (203 Czech Republic, belonging to the institution), Júlia BOHOŠOVÁ (703 Slovakia, belonging to the institution) and Tomáš BUCHLER (203 Czech Republic)

Edition

Cancers, BASEL, MDPI, 2020, 2072-6694

Other information

Language

English

Type of outcome

Článek v odborném periodiku

Field of Study

30204 Oncology

Country of publisher

Switzerland

Confidentiality degree

není předmětem státního či obchodního tajemství

References:

URL

Impact factor

Impact factor: 6.639

RIV identification code

RIV/00216224:14110/20:00118629

Organization unit

Faculty of Medicine

DOI

http://dx.doi.org/10.3390/cancers12102911

UT WoS

000584121600001

Keywords in English

metastatic renal cell carcinoma; targeted therapy; cytoreductive nephrectomy; overall survival

Abstract

V originále

Simple Summary: The treatment of metastatic renal cell carcinoma is traditionally initiated with the removal of the diseased kidney with the tumor in many patients. However, there is ongoing controversy about the benefit of kidney removal if targeted therapy is used. The present paper analyses a large cohort of patients, and the results indicate that primary tumor removal should still be strongly considered in patients who are treated with targeted therapies. The role of cytoreductive nephrectomy (CN) in treatment of locally advanced or metastatic renal cell carcinoma (mRCC) in the era of targeted therapies (TT) is still not clearly defined. The study population consisted of 730 patients with synchronous mRCC. The RenIS (Renal carcinoma Information System) registry was used as the data source. The CN/TT cohort included patients having CN within 3 months from the mRCC diagnosis and subsequently being treated with TT, while the TT cohort included patients receiving TT upfront. Median progression-free survival from the first intervention was 6.7 months in the TT arm and 9.3 months in the CN/TT patients (p < 0.001). Median overall survival was 14.2 and 27.2 months, respectively (p < 0.001). Liver metastasis, high-grade tumor, absence of CN, non-clear cell histology, and MSKCC (Memorial Sloan-Kettering Cancer Center) poor prognosis status were associated with adverse treatment outcomes. According to the results of this retrospective study, patients who underwent CN and subsequently were treated with TT had better outcomes compared to patients treated with upfront TT. The results of the study support the use of CN in the treatment algorithm for mRCC.

Links

NV18-03-00554, research and development project

Name: Molekulární klasifikace renálního buněčného karcinomu založená na expresi dlouhých nekódujících RNA a její využití v diagnostice, předpovědi prognózy a terapii

Investor: Ministry of Health of the CR

NV19-08-00250, research and development project

Name: Proteotypová klasifikace renálního karcinomu ve vztahu k prognóze a terapeutické odpovědi

Investor: Ministry of Health of the CR

Citovat

POPRACH, Alexandr, Miloš HOLÁNEK, Renata CHLOUPKOVÁ, Radek LAKOMÝ, Michal STANÍK, Ondřej FIALA, Bohuslav MELICHAR, Kateřina KOPECKOVA, Milada ZEMANOVA, Igor KISS, Igor PENKA, Júlia BOHOŠOVÁ and Tomáš BUCHLER. Cytoreductive Nephrectomy and Overall Survival of Patients with Metastatic Renal Cell Carcinoma Treated with Targeted Therapy-Data from the National Renis Registry. Cancers. BASEL: MDPI, 2020, vol. 12, No 10, p. 1-10. ISSN 2072-6694. Available from: https://dx.doi.org/10.3390/cancers12102911.

@article{1698736,
   author = {Poprach, Alexandr and Holánek, Miloš and Chloupková, Renata and Lakomý, Radek and Staník, Michal and Fiala, Ondřej and Melichar, Bohuslav and Kopeckova, Kateřina and Zemanova, Milada and Kiss, Igor and Penka, Igor and Bohošová, Júlia and Buchler, Tomáš},
   article_location = {BASEL},
   article_number = {10},
   doi = {http://dx.doi.org/10.3390/cancers12102911},
   keywords = {metastatic renal cell carcinoma; targeted therapy; cytoreductive nephrectomy; overall survival},
   language = {eng},
   issn = {2072-6694},
   journal = {Cancers},
   title = {Cytoreductive Nephrectomy and Overall Survival of Patients with Metastatic Renal Cell Carcinoma Treated with Targeted Therapy-Data from the National Renis Registry},
   url = {https://www.mdpi.com/2072-6694/12/10/2911},
   volume = {12},
   year = {2020}
}

TY  - JOUR
ID  - 1698736
AU  - Poprach, Alexandr - Holánek, Miloš - Chloupková, Renata - Lakomý, Radek - Staník, Michal - Fiala, Ondřej - Melichar, Bohuslav - Kopeckova, Kateřina - Zemanova, Milada - Kiss, Igor - Penka, Igor - Bohošová, Júlia - Buchler, Tomáš
PY  - 2020
TI  - Cytoreductive Nephrectomy and Overall Survival of Patients with Metastatic Renal Cell Carcinoma Treated with Targeted Therapy-Data from the National Renis Registry
JF  - Cancers
VL  - 12
IS  - 10
SP  - 1-10
EP  - 1-10
PB  - MDPI
SN  - 20726694
KW  - metastatic renal cell carcinoma
KW  - targeted therapy
KW  - cytoreductive nephrectomy
KW  - overall survival
UR  - https://www.mdpi.com/2072-6694/12/10/2911
L2  - https://www.mdpi.com/2072-6694/12/10/2911
N2  - Simple Summary: The treatment of metastatic renal cell carcinoma is traditionally initiated with the removal of the diseased kidney with the tumor in many patients. However, there is ongoing controversy about the benefit of kidney removal if targeted therapy is used. The present paper analyses a large cohort of patients, and the results indicate that primary tumor removal should still be strongly considered in patients who are treated with targeted therapies. The role of cytoreductive nephrectomy (CN) in treatment of locally advanced or metastatic renal cell carcinoma (mRCC) in the era of targeted therapies (TT) is still not clearly defined. The study population consisted of 730 patients with synchronous mRCC. The RenIS (Renal carcinoma Information System) registry was used as the data source. The CN/TT cohort included patients having CN within 3 months from the mRCC diagnosis and subsequently being treated with TT, while the TT cohort included patients receiving TT upfront. Median progression-free survival from the first intervention was 6.7 months in the TT arm and 9.3 months in the CN/TT patients (p < 0.001). Median overall survival was 14.2 and 27.2 months, respectively (p < 0.001). Liver metastasis, high-grade tumor, absence of CN, non-clear cell histology, and MSKCC (Memorial Sloan-Kettering Cancer Center) poor prognosis status were associated with adverse treatment outcomes. According to the results of this retrospective study, patients who underwent CN and subsequently were treated with TT had better outcomes compared to patients treated with upfront TT. The results of the study support the use of CN in the treatment algorithm for mRCC.
ER  -

POPRACH, Alexandr, Miloš HOLÁNEK, Renata CHLOUPKOVÁ, Radek LAKOMÝ, Michal STANÍK, Ondřej FIALA, Bohuslav MELICHAR, Kateřina KOPECKOVA, Milada ZEMANOVA, Igor KISS, Igor PENKA, Júlia BOHOŠOVÁ and Tomáš BUCHLER. Cytoreductive Nephrectomy and Overall Survival of Patients with Metastatic Renal Cell Carcinoma Treated with Targeted Therapy-Data from the National Renis Registry. \textit{Cancers}. BASEL: MDPI, 2020, vol.~12, No~10, p.~1-10. ISSN~2072-6694. Available from: https://dx.doi.org/10.3390/cancers12102911.

Detailed Information on Publication Record